The stock of Bristol-Myers Squibb Company (NYSE:BMY) last traded at $66.53, down -0.73% from the previous session.
Data from the available sources indicates that Bristol-Myers Squibb Company (NYSE:BMY) is covered by 24 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $92.00 and a low of $59.00, we find $81.00. Given the previous closing price of $67.02, this indicates a potential upside of 20.86 percent. BMY stock price is now -2.73% away from the 50-day moving average and -7.70% away from the 200-day moving average. The market capitalization of the company currently stands at $141.86B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
In total, 12 analysts have assigned it a hold rating, and 10 have given it a buy rating. Brokers who have rated the stock have averaged $79.97 as their price target over the next twelve months.
With the price target of $62, Jefferies recently initiated with Hold rating for Bristol-Myers Squibb Company (NYSE: BMY). On January 17, 2023, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $95, while ‘Credit Suisse’ rates the stock as ‘Neutral’.
In other news, VESSEY RUPERT, EVP & President, Research sold 50,385 shares of the company’s stock on May 03. The stock was sold for $3,378,818 at an average price of $67.06. Upon completion of the transaction, the EVP & President, Research now directly owns 47,751 shares in the company, valued at $3.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 06, Board Chair and CEO Caforio Giovanni sold 240,000 shares of the business’s stock. A total of $17,916,000 was realized by selling the stock at an average price of $74.65. This leaves the insider owning 236,104 shares of the company worth $15.71 million. Insiders disposed of 1,006,674 shares of company stock worth roughly $66.97 million over the past 1 year. A total of 0.07% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BMY stock. A new stake in Bristol-Myers Squibb Company shares was purchased by MIZUHO MARKETS CAYMAN LP during the first quarter worth $115,708,000. CANOE FINANCIAL LP invested $72,321,000 in shares of BMY during the first quarter. In the first quarter, BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in Bristol-Myers Squibb Company valued at approximately $40,071,000. HARVEST PORTFOLIOS GROUP INC. acquired a new stake in BMY for approximately $39,131,000. INVENOMIC CAPITAL MANAGEMENT LP purchased a new stake in BMY valued at around $38,287,000 in the second quarter. In total, there are 3,300 active investors with 79.40% ownership of the company’s stock.
With an opening price of $67.06 on Wednesday morning, Bristol-Myers Squibb Company (NYSE: BMY) set off the trading day. During the past 12 months, Bristol-Myers Squibb Company has had a low of $65.28 and a high of $81.43. As of last week, the company has a debt-to-equity ratio of 1.19, a current ratio of 1.40, and a quick ratio of 1.30. According to the stock market information, the enterprise value for the company is $173.17B, which is based on a 19.39 price-to-earnings ratio, a 5.16 price-to-earnings-growth ratio, and a beta of 0.43. The fifty day moving average price for BMY is $68.37 and a two-hundred day moving average price translates $72.05 for the stock.
The latest earnings results from Bristol-Myers Squibb Company (NYSE: BMY) was released for Mar, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $2.05, beating analysts’ expectations of $1.97 by 0.08. This compares to $0.59 EPS in the same period last year. The net profit margin was 15.90% and return on equity was 22.80% for BMY. The company reported revenue of $11.34 billion for the quarter, compared to $11.65 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.67 percent. For the current quarter, analysts expect BMY to generate $11.87B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 05/01/2023. Investors who held shares on 04/10/2023 were paid a $0.57 dividend. On an annualized basis, this represents a $2.28 dividend and a 3.43% percent yield. There was an ex-dividend date of 04/06/2023 for this dividend. In terms of dividend payout ratio, BMY is presently at 63.40%.
Bristol-Myers Squibb Company(BMY) Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
